DOI: 10.1055/s-00000020

Geburtshilfe und Frauenheilkunde

References

Finn RS, Crown JP, Lang I et al.
Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs. letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC).

Cancer Res 2012;
72 (Suppl. 24) 91s

Download Bibliographical Data

Search in:
Access: